Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04539886 · ClinicalTrials.gov registry record · NA
Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions
A NA study, sponsored by Pulse Biosciences.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT04539886 is a NA study that has completed, run by Pulse Biosciences. The registered enrollment target is 60 participants.
The verdict
NCT04539886, a NA study, has completed, sponsored by Pulse Biosciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study is designed as a multi-center, single-blinded, prospective, randomized, study to compare the safety and effectiveness of the CellFX System to the comparator group, Electrodessication for the treatment of SH lesions in healthy adult subjects.
Interventions
- DEVICE CellFX System
- DEVICE Intralesional Electrodesiccation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-09-28 |
| Est. Completion | 2021-11-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04539886
The ClinicalTrials.gov registry entry for NCT04539886 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pulse Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CellFX System is the first listed.
NCT04539886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04539886 about?
NCT04539886 is a clinical study titled "Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions". This study is designed as a multi-center, single-blinded, prospective, randomized, study to compare the safety and effectiveness of the CellFX System to the comparator group, Electrodessication for the treatment of SH lesions in healthy adult subjects.
What is the current status of trial NCT04539886?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2020-09-28. Estimated completion is 2021-11-18.
What interventions are being tested in trial NCT04539886?
The interventions under investigation include: CellFX System (DEVICE), Intralesional Electrodesiccation (DEVICE).
Who is sponsoring clinical trial NCT04539886?
This trial is sponsored by Pulse Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.